Brief: Optiscan Imaging Signs Agreement With Long Grove Pharmaceuticals
23/06/2025 02:37
June 23 (Reuters) - Optiscan Imaging Ltd OIL.AX: SIGNS AGREEMENT WITH LONG GROVE PHARMACEUTICALS UNDER DEAL, COS TO DEVELOP NEW INTENDED USES FOR LONG GROVE'S INTRAVENOUS FLUORESCEIN SODIUM CONTRAST AGENT Further company coverage: OIL.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Optiscan Imaging
See all newsAustralia's Optiscan rises after FDA filing for surgery imaging device
Brief: Optiscan Imaging Lodges US FDA 510(K) Submission For Inform Digital Pathology Device
Australia's Optiscan rises after imaging more than 80 cases in ACL study
Australia's Optiscan Imaging gains on signing new cross-border research deal
Brief: Optiscan Imaging Lodges US FDA Dossier For Inspecta For Veterinary Market